Abstract
Cardiovascular drugs are characterized by wide inter-individual variability in dose/plasma concentration/ response (therapeutic and/or toxic) relationships. Therefore, some patients achieve good therapeutic response to their drug therapy, while others do not. Also, some patients experience adverse effects, which vary from mild to life-threatening. The source of variability in patients response to cardiovascular drugs may be of pharmacokinetic and/or pharmacodynamic origin. Many factors can potentially affect both of them such as genetics, gender, age, disease state, environmental factors like smoking and food, possible drug-drug interactions, and ethnicity (race). Cardiovascular pharmacogenomics is a new field that focus on the roles of genetic polymorphisms in drug metabolizing enzymes and drug targets in development of variable drug response.
Keywords: CYP2D6 enzyme, pharmacodynamic, P-glycoprotein (Pgp), MDR-1 gene, Hepatic disease, Carvedilol, Angiotensin Converting Enzyme Inhibitors
Current Clinical Pharmacology
Title: Variability in Response to Cardiovascular Drugs
Volume: 1 Issue: 1
Author(s): Ehab S. ELDesoky, Hartmut Derendorf and Ulrich Klotz
Affiliation:
Keywords: CYP2D6 enzyme, pharmacodynamic, P-glycoprotein (Pgp), MDR-1 gene, Hepatic disease, Carvedilol, Angiotensin Converting Enzyme Inhibitors
Abstract: Cardiovascular drugs are characterized by wide inter-individual variability in dose/plasma concentration/ response (therapeutic and/or toxic) relationships. Therefore, some patients achieve good therapeutic response to their drug therapy, while others do not. Also, some patients experience adverse effects, which vary from mild to life-threatening. The source of variability in patients response to cardiovascular drugs may be of pharmacokinetic and/or pharmacodynamic origin. Many factors can potentially affect both of them such as genetics, gender, age, disease state, environmental factors like smoking and food, possible drug-drug interactions, and ethnicity (race). Cardiovascular pharmacogenomics is a new field that focus on the roles of genetic polymorphisms in drug metabolizing enzymes and drug targets in development of variable drug response.
Export Options
About this article
Cite this article as:
ELDesoky S. Ehab, Derendorf Hartmut and Klotz Ulrich, Variability in Response to Cardiovascular Drugs, Current Clinical Pharmacology 2006; 1 (1) . https://dx.doi.org/10.2174/157488406775268273
DOI https://dx.doi.org/10.2174/157488406775268273 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Renal Function Impairment in Patients Undergoing Elective EVAR vs. Elective Open Repair During Follow up Period: A Systematic Review of the Literature
Current Vascular Pharmacology Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design Alumina Sulfuric Acid: An Efficient Heterogeneous Catalyst for the Synthesis of Amidoalkyl Naphthols
Letters in Organic Chemistry Extracellular Matrix Remodeling in Hypertension
Current Hypertension Reviews Dengue Fever: A Worldwide Threat An Overview of the Infection Process, Environmental Factors for a Global Outbreak, Diagnostic Platforms and Vaccine Developments
Current Topics in Medicinal Chemistry Plasma Substitutes Therapy in Pediatrics
Current Drug Targets Metabolite Identification and Profiling in Drug Design: Current Practice and Future Directions
Current Pharmaceutical Design The Roles of Corticotropin Releasing Factor (CRF) in Responses to Emotional Stress: Is CRF Release a Cause or Result of Fear/Anxiety?
CNS & Neurological Disorders - Drug Targets Toll-Like Receptors and their Role in Renal Pathologies
Inflammation & Allergy - Drug Targets (Discontinued) Inhibition of Endotoxin Response by Synthetic TLR4 Antagonists
Current Topics in Medicinal Chemistry Chemical Constituents and Biological Activities of Cordia myxa L.: A Review
The Natural Products Journal Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology Synthesis and Characterization of Water-soluble Conjugates of Cabazitaxel Hemiesters-Dextran
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design Transdermal Delivery: Product and Patent Update
Recent Patents on Drug Delivery & Formulation Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Vasoconstrictor Therapy for Hepatorenal Syndrome in Liver Cirrhosis
Current Pharmaceutical Design Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology